Systemic lupus erythematosus (SLE)
B-cell-targeted therapies have become a mainstay of treatment for a range of autoimmune diseases, including rheumatoid arthritis, vasculitis and lupus. However, treatment responses to B-cell depletion with rituximab may be variable and have led to mixed results in diseases such as lupus. Although disease heterogeneity is likely one factor underlying this variable clinical response, another possibility is that certain subsets of B-cells contributing to disease pathogenesis are not adequately depleted. This session will summarize new approaches to B-cell targeting, including second-generation anti-CD20 antibodies, CAR-T therapy and proteasome inhibition.